Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

123.45USD
23 May 2018
Change (% chg)

$0.54 (+0.44%)
Prev Close
$122.91
Open
$122.87
Day's High
$123.97
Day's Low
$122.75
Volume
1,809,846
Avg. Vol
2,327,082
52-wk High
$148.32
52-wk Low
$121.28

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $329,663.09
Shares Outstanding(Mil.): 2,682.15
Dividend: 0.90
Yield (%): 2.93

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.67 28.66 32.90
EPS (TTM): 5.42 -- --
ROI: 11.91 13.20 12.74
ROE: 22.22 14.95 14.64

J&J hit with $21.7 million verdict in another talc asbestos cancer case

NEW YORK Johnson & Johnson and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder.

May 23 2018

J&J hit with $21.7 mln verdict in another talc asbestos cancer case

NEW YORK, May 23 Johnson & Johnson and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder.

May 23 2018

EU mergers and takeovers (May 23)

BRUSSELS, May 23 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

May 23 2018

Johnson & Johnson scraps Alzheimer's trials on safety concerns

Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.

May 18 2018

Johnson & Johnson scraps Alzheimer's trials on safety concerns

May 18 Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.

May 18 2018

Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

May 15 2018

UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

* Shares of Amgen, JNJ fall in afternoon trading (Adds analyst comments, updates shares)

May 15 2018

J&J defends itself in trial over baby powder asbestos claims

A trial for a lawsuit alleging that Johnson & Johnson Baby Powder was responsible for the death of a woman due to her exposure to cancer-causing asbestos began in South Carolina on Monday in the latest case against the healthcare conglomerate and a supplier over their talc-based products.

May 14 2018

RPT-J&J defends itself in trial over baby powder asbestos claims

May 14 A trial for a lawsuit alleging that Johnson & Johnson Baby Powder was responsible for the death of a woman due to her exposure to cancer-causing asbestos began in South Carolina on Monday in the latest case against the healthcare conglomerate and a supplier over their talc-based products.

May 14 2018

RPT-J&J defends itself in trial over baby powder asbestos claims

May 14 A trial for a lawsuit alleging that Johnson & Johnson Baby Powder was responsible for the death of a woman due to her exposure to cancer-causing asbestos began in South Carolina on Monday in the latest case against the healthcare conglomerate and a supplier over their talc-based products.

May 14 2018

Earnings vs. Estimates